SCI-PUB

BMT & CAR-T cell therapy

Diagnostic yield for video capsule endoscopy in gastrointestinal graft- versus -host disease: a systematic review and metaanalysis.

The role of video capsule endoscopy in diagnosing or dismissing graft-versus-host disease is not yet established and requires further studies. However, the modality appears safe in this cohort.

DOI: 10.1080/00365521.2023.2175621

Varkey J, Jonsson V, Hessman E, De Lange T, Hedenström P, Oltean M

Scandinavian journal of gastroenterology, 2023-02-07

[New European approvals: Axicabtagene ciloleucel CAR-T cells - Diffuse Large B Cell Lymphoma after one prior line of therapy].

No abstract text is available for this article

DOI: 10.1016/j.bulcan.2022.12.010

Messéant O, Manson G

Bulletin du cancer, 2023-02-07

NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma.

No abstract text is available for this article

DOI: 10.1016/S1470-2045(23)00054-2

Wilkinson E

The Lancet. Oncology, 2023-02-07

Construction of CAR-T Cells Targeting TM4SF1 and its Anti-tumor Capacity in Ovarian Cancer.

Ovarian cancer (OC) is the most lethal gynecological malignancy with a 5-year survival rate of 49.1% on average...

DOI: 10.1016/j.imlet.2023.01.011

Shen Y, Liu G, Zhang Q, Tian X, Ouyang L, Zhang L

Immunology letters, 2023-02-06

Clinical benefit of low-dose anti-thymocyte globulin-thymoglobulin as a graft-versus-host disease prophylaxis in patients receiving allogeneic peripheral blood stem cell transplantation from human leukocyte antigen-identical donors.

Low-dose ATG-T could be beneficial for patients receiving PBSCT from HLA-identical donors.

DOI: 10.1016/j.jtct.2023.01.026

Takeuchi Y, Miyao K, Negishi S, Ohara F, Motegi K, Wakabayashi H, Yokota H, Kuwano S, Sawa H, Inagaki Y, Sawa M

Transplantation and cellular therapy, 2023-02-06

Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation.

The severity of T cell-mediated gastrointestinal (GI) diseases such as graft-versus-host disease (GVHD) and inflammatory bowel diseases correlates with a decrease in the diversity of the host gut microbiome composition characterized by loss of obligate anaerobic commensals...

DOI: 10.1016/j.immuni.2023.01.007

Seike K, Kiledal A, Fujiwara H, Henig I, Burgos da Silva M, van den Brink MRM, Hein R, Hoostal M, Liu C, Oravecz-Wilson K, Lauder E, Li L, Sun Y, Schmidt TM, Shah YM, Jenq RR, Dick G, Reddy P

Immunity, 2023-02-06

Single-cell transcriptomics reveals immune reconstitution in R/R T-ALL/LBL patients with donor-derived CD7 CAR-T therapy.

Our data revealed cellular level dynamics of immune homeostasis of CD7 CAR-T therapy, which is valuable for optimizing the treatment of R/R T-ALL/LBL.

DOI: 10.1158/1078-0432.CCR-22-2924

Chen W, Shi H, Liu Z, Yang F, Liu J, Zhang L, Wu Y, Xia Y, Ou Y, Li R, Zhang T, Zhang J, Ke X, Hu K, Yu J

Clinical cancer research : an official journal of the American Association for Cancer Research, 2023-02-04

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

Chimeric antigen receptor T-cell therapy (CART) has extended survival of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)...

DOI: 10.1182/bloodadvances.2022009309

Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV

Blood advances, 2023-02-04

RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function.

CAR-T therapy has shown successful in the treatment of certain types of hematological malignancy, while the efficacy of CAR-T cell in treating solid tumors has been limited due to the exhaustion of CAR-T caused by the tumor microenvironment in solid tumors...

DOI: 10.1007/s12032-022-01913-7

Zhu X, Li W, Gao J, Shen J, Xu Y, Zhang C, Qian C

Medical oncology (Northwood, London, England), 2023-02-04

Efficacy and safety of dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B-cell lymphoid malignancies: a systematic review and meta-analysis.

Dual-targeting chimeric antigen receptor (CAR)-T cell therapy has been proposed as a potential solution for overcoming antigen escape during anti-CD19 CAR-T treatment...

DOI: 10.1089/hum.2022.183

Min Y, Zhang Q, Kong F, Qi L, Pu Y, Qiu L, Wang J, Li F

Human gene therapy, 2023-02-04

Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.

This cross-sectional study aimed to develop and validate a patient-reported outcomes (PROs) assessment tool to assess symptom burden and daily functioning in patients after chimeric antigen receptor (CAR) T-cell therapy, the MD Anderson Symptom Inventory (MDASI-CAR)...

DOI: 10.1111/bjh.18677

Wang XS, Srour SA, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, Kamal M, Shen SE, Cleeland C, Kebriaei P, Rezvani K, Neelapu S, Ahmed S, Shpall E

British journal of haematology, 2023-02-04

Progress in risk-adapted acute GVHD therapy.

No abstract text is available for this article

DOI: 10.1182/blood.2022018021

Pidala J

Blood, 2023-02-03

Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease.

We performed transcriptomic analyses on freshly frozen (n=21) and paraffin embedded (n=35) gastrointestinal (GI)biopsies from children with and without acute GI graft versus host disease (GVHD) to study differential gene expressions...

DOI: 10.3324/haematol.2022.282035

Khandelwal P, Lounder DT, Bartlett A, Haberman Y, Jegga AG, Ghandikota S, Koo J, Luebbering N, Leino D, Abdullah S, Loveless M, Minar P, Lake K, Litts B, Karns R, Nelson AS, Denson LA, Davies SM

Haematologica, 2023-02-03

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.

The results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising treatment modality for patients with relapsed or refractory multiple myeloma and deserves further testing.

DOI: 10.1016/S2352-3026(22)00372-6

Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, Fu S, Zhou X, Tang Y, Ding X, Kuang J, He XP, Hu Y, Huang H

The Lancet. Haematology, 2023-02-03

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterised...

DOI: 10.1182/bloodadvances.2022009019

Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor AJ, Jones CH, Uttenthal BJ, Johnson RJ, Sanderson R, Cheok KP, Marzolini MAV, Townsend WM, O'Reilly M, Kirkwood AA, Kuhnl A

Blood advances, 2023-02-02

Abatacept GVHD Prophylaxis in Unrelated Hematopoietic Cell Transplantation for Pediatric Bone Marrow Failure.

Hematopoietic cell transplantation (HCT) is the only readily available cure for many life-threatening pediatric non-malignant diseases (NMD), but most patients lack a matched related donor and are at higher risk for graft-versus-host disease (GVHD)...

DOI: 10.1182/bloodadvances.2022008545

Stenger EO, Watkins B, Rogowski K, Chiang KY, Haight AE, Leung K, Qayed M, Raghunandan S, Suessmuth Y, Kean LS, Horan JT

Blood advances, 2023-02-02

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM)...

DOI: 10.3324/haematol.2022.281339

García-Guerrero E, Rodríguez-Lobato LG, Sierro-Martínez B, Danhof S, Bates S, Frenz S, Härtle L, Götz R, Sauer M, Rasche L, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M, Prommersberger SR

Haematologica, 2023-02-02

Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.

Although up to 80 % of Hodgkin lymphoma (HL) patients are cured with first-line therapy, relapsed/refractory HL remains a major clinical obstacle and is fatal for patients who are not candidates for autologous stem cell transplantation (ASCT) or relapse after treatment...

DOI: 10.1016/j.critrevonc.2023.103923

Maaroufi M

Critical reviews in oncology/hematology, 2023-02-06

Pregnancy complications after allogeneic hematopoietic stem cells transplantation: Focus on the placenta.

INTRODUCTION: hematopoietic stem cells transplantation (HSCT) is a treatment option for malignant and non-malignant haematological diseases.

DOI: 10.1016/j.placenta.2022.12.010

Gazzo I, Massarotti C, Chiodi S, Spinelli S, Gualandi F, Passamonti U, Fulcheri E, Angelucci E, Cagnacci A

Placenta, 2023-02-04

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety.

Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population...

DOI: 10.1016/j.neo.2022.100870

Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, Wein A, Brown C, Beebe A, Kong A, Kirkey D, Lee BM, Leary SES, Crotty EE, Hoeppner C, Holtzclaw S, Wilson AL, Gustafson JA, Foster JB, Iliff JJ, Goldstein HE, Browd SR, Lee A, Oje

Neoplasia (New York, N.Y.), 2023-02-02

Machine learning-based injury severity prediction of level 1 trauma center enrolled patients associated with car-to-car crashes in Korea.

Injury prediction models enables to improve trauma outcomes for motor vehicle occupants in accurate decision-making and early transport to appropriate trauma centers...

DOI: 10.1016/j.compbiomed.2022.106393

Kong JS, Lee KH, Kim OH, Lee HY, Kang CY, Choi D, Kim SC, Jeong H, Kang DR, Sung TE

Computers in biology and medicine, 2023-02-02

Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.

Given ruxolitinib's efficacy in SR-GVHD, use of this drug should not be limited by the fear of viral reactivation; however, our present results emphasize the importance of monitoring the viral load.

DOI: 10.1016/j.leukres.2022.107005

Lebon D, Dujardin A, Caulier A, Joris M, Charbonnier A, Gruson B, Quint M, Castelain S, François C, Lacassagne MN, Guillaume N, Marolleau JP, Morel P

Leukemia research, 2023-02-02

Fetal allotransplant recipients are resistant to graft-versus-host disease.

In utero hematopoietic cell transplantation (IUHCT) is an experimental treatment for congenital hemoglobinopathies, including Sickle cell disease and thalassemias...

DOI: 10.1016/j.exphem.2022.12.004

Riley JS, McClain LE, Stratigis JD, Coons BE, Bose SK, Dave A, White BM, Li H, Loukogeorgakis SP, Fachin CG, Dias AIBS, Flake AW, Peranteau WH

Experimental hematology, 2023-02-06

RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.

Autologous chimeric antigen receptor (CAR) T cells have recently emerged as potent tools in the fight against cancer, with promising therapeutic efficacy against hematological malignancies...

DOI: 10.1158/0008-5472.CAN-22-2155

Schaible P, Bethge W, Lengerke C, Haraszti RA

Cancer research, 2023-02-04

Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.

Our findings improve the understanding of the impact of cytokines on hematopoietic functions, which could contribute to the mechanism investigation and exploration of potential intervention strategies.

DOI: 10.1016/j.jcyt.2022.11.001

Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, Zhang M, Zhao H, Ding S, Chang AH, Xu H, Hu Y, Wei G, Huang H

Cytotherapy, 2023-02-02

Cellular senescence marker p16 and NFKB1 gene polymorphisms in lower gastro-intestinal acute graft versus host disease.

Our results address possible new mechanisms that may lead to better understanding of HSCT-related immune complications. Cellular senescence may bring novel approaches in GVHD diagnostics and therapy.

DOI: 10.1016/j.trim.2022.101768

Kuba A, Raida L, Brychtova S, Flodr P, Mrazek F, Kriegova E, Faber E, Papajik T

Transplant immunology, 2023-02-02

Rehabilitation of patients after CAR T-cell therapy. Experiences on 5 patients.

As far as we know, this is the first report on several patients after CAR T-cell therapy. Based on the limited data, there is no reason to withhold a rehabilitation stay from patients after CAR T-cell therapy.

DOI: 10.1016/j.trim.2022.101770

Kiefer T, Lüders C, Völler H, Daeschlein G

Transplant immunology, 2023-02-02

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.

Patients in the high-risk letermovir group had outcomes that were comparable to the lower risk "non-letermovir" group. There was no significant difference in CMV D + 100 reactivation between high-risk patients who did not receive letermovir compared to the patients who did. While other studies have shown that early initiation of letermovir may be associated with improved outcomes, our study shows that the use of letermovir with initiation at 21 days may not necessarily translate to improved secondary outcomes such as overall survival. Further prospective studies evaluating the time of initiating therapy and outcomes are needed.

DOI: 10.1016/j.trim.2022.101769

Dwabe S, Hsiao M, Ali A, Rodman J, Savitala-Damerla L, Nazaretyan S, Kimberly Schiff NP, Tam E, Ladha A, Woan K, Chaudhary P, Yaghmour G

Transplant immunology, 2023-02-02

Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.

Patients undergoing CAR-T report overly optimistic perception of their prognosis and have high rates of psychological distress. Higher emotional coping with prognosis and adaptive response were associated with better QOL and less psychological distress, underscoring the need to develop interventions to promote coping with this treatment.

DOI: 10.1002/cncr.34557

Dhawale TM, Johnson PC, Gaballa MR, Nelson AM, Lavoie MW, Boateng KY, Greydanus C, Frigault MJ, El-Jawahri A

Cancer, 2023-02-02

A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.

Patients and caregivers would benefit from early and ongoing support from palliative care, allied-health professionals and psychology. As indications for CAR-T therapy expand, there is an urgent need for multi-centre studies incorporating patient-reported outcome data to ensure patient-centred service delivery.

DOI: 10.1177/02692163221138880

Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R

Palliative medicine, 2023-02-02

Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.

Taken together, the cytotoxic function of αM.CAR/SR T cells was enhanced over the αM.CAR T cells, which are potential to be further tested for CCA treatment.

DOI: 10.1016/j.jcyt.2022.10.006

Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT

Cytotherapy, 2023-02-02

Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy.

No abstract text is available for this article

DOI: 10.1007/s00277-022-05045-w

Davis JA, Misniakiewicz J, Hendrickson L, McGann M, Herbst A, Hess BT

Annals of hematology, 2023-02-02

Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.

We reported encouraging results of ruxolitinib monotherapy in the prevention of aGVHD and maintenance of GVL for post-transplantation relapsed patients, even though being at high risk with poor initial prognosis.

DOI: 10.1016/j.trim.2022.101743

Tang Y, Yang D, Xie R, Zhong Z, You Y

Transplant immunology, 2023-02-02

Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.

Infections after CTI were closely associated with more lines of prior treatment, longer duration of ANC<500 cells/mm3, higher grade CRS and poor treatment response. Infections tended to occur in the early stage after CTI in patients with more lines of prior treatment and higher grade CRS.

DOI: 10.1016/j.jiac.2022.10.012

Zhou D, Wang Y, Cheng H, Zhu L, Chen W, Li H, Zhang X, Xia J, Qi Y, Ma S, Zhu F, Yan Z, Qi K, Sang W, Sun H, Li D, Cao J, Li Z, Xu K

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023-02-02

Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.

No abstract text is available for this article

DOI: 10.1016/j.jcyt.2022.10.001

Xu H, Lv Q, Huang L, Cao W, Wang J, Meng F, Li C, Zheng M, Chen L, Mu K, Cheng J, Zhu L, Zhou J, Zhang Y, Wang N, Cao Y

Cytotherapy, 2023-02-02

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant.

No abstract text is available for this article

DOI: 10.3324/haematol.2022.281719

Chen G, Herr M, Nowak J, Ho C, Almyroudis N, Attwood K, Bonnewell J, Walsh M, Segal B, Ross M, McCarthy P, Hahn T

Haematologica, 2023-02-02

Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.

Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation...

DOI: 10.1007/s12185-022-03471-0

Oyama T, Matsuda K, Honda A, Maki H, Masamoto Y, Murakami D, Toya T, Sakurai M, Kataoka K, Doki N, Kurokawa M

International journal of hematology, 2023-02-02

Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.

No abstract text is available for this article

DOI: 10.1111/bjh.18500

Li C, Liu J, Deng J, Xu J, Kang Y, Luo W, Chen L, Hu Y, Mei H

British journal of haematology, 2023-02-04

High frequency of hyperglycaemia observed during CAR T-cell treatment.

No abstract text is available for this article

DOI: 10.1111/dme.14969

Tienstra M, de Boer JW, van Doesum JA, van Meerten T, van Dijk PR

Diabetic medicine : a journal of the British Diabetic Association, 2023-02-02

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes.

No abstract text is available for this article

DOI: 10.3324/haematol.2022.281957

Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN

Haematologica, 2023-02-02

The Role of Sialendoscopy in Parotid Duct Stenosis in Graft-Versus-Host Disease.

Sialendoscopy, a minimally invasive procedure for concurrent diagnosis and treatment of salivary gland ductal pathologies, was used to alleviate recurrent left parotid gland swelling and dry mouth in a 58-year-old man with chronic graft-versus-host disease.

DOI: 10.1002/lary.30402

Hansen EE, Mitchell MB, Rahmati RW

The Laryngoscope, 2023-02-02

Effective treatment of low-risk acute GVHD with itacitinib monotherapy.

The standard primary treatment for acute graft-versus-host disease (GVHD) requires prolonged, high-dose systemic corticosteroids (SCSs) that delay reconstitution of the immune system...

DOI: 10.1182/blood.2022017442

Etra A, Capellini A, Alousi A, Al Malki MM, Choe H, DeFilipp Z, Hogan WJ, Kitko CL, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Rösl

Blood, 2023-02-03

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against - mutant acute myeloid leukemia and -rearranged acute lymphoblastic leukemia.

Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma...

DOI: 10.3324/haematol.2022.281456

Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ

Haematologica, 2023-02-02

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.

CD19-specific chimeric antigen receptor (CD19-CAR) T-cell therapies mediate durable responses in late-stage B-cell malignancies, but can be complicated by a potentially severe immune effector cell-associated neurotoxicity syndrome (ICANS)...

DOI: 10.3324/haematol.2022.281110

Berger SC, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk FA

Haematologica, 2023-02-02

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Recently, chimeric antigen receptor T cell (CAR-T) therapy has received increasing attention as an adoptive cellular immunotherapy that targets tumors...

DOI: 10.1007/s00262-022-03238-w

Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, Li J, Chen Z, Jiang L, Zhang Y, Shi R, Ma L, Jia S, Zhang Y, Zhang Q, Liang J, Yao S, Hu Z, Guo Z

Cancer immunology, immunotherapy : CII, 2023-02-02

Durable discontinuation of systemic therapy for chronic graft--host disease: myth or reality?

No abstract text is available for this article

DOI: 10.3324/haematol.2022.281114

Pavletic SZ, Schultz KR

Haematologica, 2023-02-02

Durable discontinuation of systemic therapy in patients affected by chronic graft--host disease.

Successful treatment of chronic graft-versus-host disease (GvHD) often requires long-term systemic therapy (ST)...

DOI: 10.3324/haematol.2021.279814

Chen GL, Onstad L, Martin PJ, Carpenter P, Pidala J, Arai S, Cutler C, Hamilton BK, Lee SJ, Arora M

Haematologica, 2023-02-02

Predictors of kidney complications and analysis of hypertension in children with allogeneic hematopoietic stem cell transplantation.

Incidence of AKI is higher in pediatric HSCT patients with primary malignant disease and those with documented viral infection. Our study highlights the beneficial role of 24-h ABPM as a routine part of standard care of pediatric HSCT recipients.

DOI: 10.1007/s00467-022-05599-x

Gurbanov A, Gülhan B, Kuşkonmaz B, Okur FV, Ozaltin F, Düzova A, Çetinkaya DU, Topaloglu R

Pediatric nephrology (Berlin, Germany), 2023-02-02

Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft--host disease.

No abstract text is available for this article

DOI: 10.3324/haematol.2022.281168

Pidala J, Anasetti C

Haematologica, 2023-02-02

Наверх

BMT & CAR-T cell therapy

Diagnostic yield for video capsule endoscopy in gastrointestinal graft- versus -host disease: a systematic review and metaanalysis.

[New European approvals: Axicabtagene ciloleucel CAR-T cells - Diffuse Large B Cell Lymphoma after one prior line of therapy].

NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma.

Construction of CAR-T Cells Targeting TM4SF1 and its Anti-tumor Capacity in Ovarian Cancer.

Clinical benefit of low-dose anti-thymocyte globulin-thymoglobulin as a graft-versus-host disease prophylaxis in patients receiving allogeneic peripheral blood stem cell transplantation from human leukocyte antigen-identical donors.

Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation.

Single-cell transcriptomics reveals immune reconstitution in R/R T-ALL/LBL patients with donor-derived CD7 CAR-T therapy.

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma.

RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function.

Efficacy and safety of dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B-cell lymphoid malignancies: a systematic review and meta-analysis.

Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.

Progress in risk-adapted acute GVHD therapy.

Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease.

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Abatacept GVHD Prophylaxis in Unrelated Hematopoietic Cell Transplantation for Pediatric Bone Marrow Failure.

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy.

Pregnancy complications after allogeneic hematopoietic stem cells transplantation: Focus on the placenta.

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety.

Machine learning-based injury severity prediction of level 1 trauma center enrolled patients associated with car-to-car crashes in Korea.

Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.

Fetal allotransplant recipients are resistant to graft-versus-host disease.

RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.

Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.

Cellular senescence marker p16 and NFKB1 gene polymorphisms in lower gastro-intestinal acute graft versus host disease.

Rehabilitation of patients after CAR T-cell therapy. Experiences on 5 patients.

Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.

Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy.

A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.

Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.

Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy.

Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion.

Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.

Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.

Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant.

Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.

Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.

High frequency of hyperglycaemia observed during CAR T-cell treatment.

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes.

The Role of Sialendoscopy in Parotid Duct Stenosis in Graft-Versus-Host Disease.

Effective treatment of low-risk acute GVHD with itacitinib monotherapy.

Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against - mutant acute myeloid leukemia and -rearranged acute lymphoblastic leukemia.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy.

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Durable discontinuation of systemic therapy for chronic graft--host disease: myth or reality?

Durable discontinuation of systemic therapy in patients affected by chronic graft--host disease.

Predictors of kidney complications and analysis of hypertension in children with allogeneic hematopoietic stem cell transplantation.

Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft--host disease.

Contact Us

Log In

Password recovery